MCID: LYD001
MIFTS: 45

Leydig Cell Tumor

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leydig Cell Tumor

MalaCards integrated aliases for Leydig Cell Tumor:

Name: Leydig Cell Tumor 11 53 43 14 16 71
Leydig Cell Tumor, Benign 71
Leydig Cell Neoplasm 11
Tumor, Leydig Cell 38

Classifications:



External Ids:

Disease Ontology 11 DOID:2696
MeSH 43 D007984
NCIt 49 C3188 C4213
SNOMED-CT 68 45002009 77870005
UMLS 71 C0023601 C0334409 C0334410

Summaries for Leydig Cell Tumor

Disease Ontology: 11 A sex cord-gonadal stromal tumor that secretes testosterone characterized by excessive proliferation of Leydig cells located in ovary or testicle.

MalaCards based summary: Leydig Cell Tumor, also known as leydig cell tumor, benign, is related to sertoli-leydig cell tumor and gynecomastia. An important gene associated with Leydig Cell Tumor is CALB2 (Calbindin 2), and among its related pathways/superpathways are Metabolism of steroids and Glucose / Energy Metabolism. The drugs Bevacizumab and Nivolumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, testis and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Related Diseases for Leydig Cell Tumor

Diseases related to Leydig Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 416)
# Related Disease Score Top Affiliating Genes
1 sertoli-leydig cell tumor 32.3 SYP INSL3 INHA HSD3BP4 CYP17A1 CALB2
2 gynecomastia 31.1 PRL INHA GNRH1 ESR1 CYP19A1
3 precocious puberty 30.9 LHCGR GNRH1 CYP21A2
4 alopecia, androgenetic, 1 30.8 CYP21A2 CYP19A1
5 androgen insensitivity syndrome 30.7 NR5A1 INSL3 CYP17A1
6 endodermal sinus tumor 30.7 KIT INHA AFP
7 testicular cancer 30.6 TP53 KIT INSL3 GNRH1 ESR1 CALB2
8 appendix adenocarcinoma 30.6 TP53 SYP
9 estrogen excess 30.6 PRL GNRH1 ESR1 CYP19A1
10 adrenogenital syndrome 30.6 SYP INHA CYP21A2
11 hydrocele 30.5 ESR1 CALB2 AFP
12 leiomyoma, uterine 30.5 GNRH1 ESR1 CYP19A1
13 precocious puberty, male-limited 30.4 LHCGR GNRH1 CYP21A2 CYP19A1
14 rete testis adenocarcinoma 30.4 CALB2 AFP
15 endometrial hyperplasia 30.4 TP53 ESR1 CYP19A1 CYP17A1
16 acne 30.4 PRL CYP21A2 CYP19A1 CYP17A1
17 germ cell cancer 30.4 TP53 KIT AFP
18 mixed germ cell-sex cord neoplasm 30.3 KIT CALB2
19 blastoma 30.3 TP53 SYP KIT AFP
20 adrenal adenoma 30.2 CYP21A2 CYP17A1 CYP11A1
21 cystadenoma 30.2 SYP KIT INHA CALB2 AFP
22 seminoma 30.2 TP53 KIT INHA ESR1 AFP
23 amenorrhea 30.1 PRL NR5A1 LHCGR GNRH1 CYP19A1 CYP17A1
24 adenomyosis 30.1 TP53 ESR1 CYP19A1
25 serous cystadenocarcinoma 30.1 TP53 ESR1 CALB2
26 cystadenofibroma 30.1 TP53 CALB2 AFP
27 peutz-jeghers syndrome 30.1 TP53 INHA CYP19A1
28 adenoma 30.0 TP53 SYP PRL LHCGR
29 mature teratoma 30.0 TP53 SYP KIT AFP
30 varicocele 30.0 TP53 PRL GNRH1 ESR1
31 azoospermia 30.0 PRL NR5A1 KIT INSL3 GNRH1 ESR1
32 sertoli cell tumor 30.0 SYP NR5A1 INHA CYP19A1 CALB2 AFP
33 adrenal rest tumor 30.0 INSL3 CYP21A2 CYP11A1
34 hyperprolactinemia 30.0 PTHLH PRL GNRH1
35 oligospermia 30.0 PRL KIT GNRH1
36 teratoma 30.0 TP53 SYP KIT ESR1 CALB2 AFP
37 embryonal carcinoma 29.9 TP53 NR5A1 KIT AFP
38 hypogonadism 29.9 PRL LHCGR GNRH1 CYP19A1
39 cystic teratoma 29.9 TP53 SYP CALB2 AFP
40 benign teratoma 29.9 TP53 SYP CALB2 AFP
41 male infertility 29.9 KIT INSL3 INHA GNRH1 ESR1 CYP21A2
42 complete androgen insensitivity syndrome 29.9 NR5A1 LHCGR INSL3 CYP19A1 CYP17A1
43 ovarian cyst 29.8 PRL GNRH1 ESR1 CYP19A1 AFP
44 gastrointestinal stromal tumor 29.8 TP53 SYP KIT ESR1
45 leiomyoma 29.7 TP53 KIT GNRH1 ESR1 CYP19A1 CYP17A1
46 hyperandrogenism 29.6 PRL INSL3 HSD3BP4 GNRH1 CYP21A2 CYP19A1
47 inguinal hernia 29.6 NR5A1 KIT INSL3 GNRH1 CALB2 AFP
48 endometrial cancer 29.5 TP53 KIT INHA GNRH1 ESR1 CYP19A1
49 myoma 29.5 TP53 PRL KIT GNRH1 ESR1 CYP19A1
50 anovulation 29.2 PRL LHCGR GNRH1 CYP21A2 CYP19A1 CYP17A1

Graphical network of the top 20 diseases related to Leydig Cell Tumor:



Diseases related to Leydig Cell Tumor

Symptoms & Phenotypes for Leydig Cell Tumor

GenomeRNAi Phenotypes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

25 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.88 CYP11A1 CYP21A2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.88 NR5A1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.88 CYP21A2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.88 CYP11A1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.88 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.88 CYP11A1 TP53
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.88 NR5A1 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.88 CYP21A2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.88 CYP21A2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.88 CYP21A2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.88 CYP11A1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.88 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.88 NR5A1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.88 CYP11A1 CYP21A2 NR5A1 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.88 CYP21A2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.88 TP53
17 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.88 TP53
18 Increased shRNA abundance (Z-score > 2) GR00366-A-20 9.88 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.88 NR5A1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.88 CYP21A2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-206 9.88 CYP21A2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.88 CYP21A2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.88 CYP21A2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.88 TP53
25 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.88 TP53
26 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.88 CYP11A1 NR5A1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-62 9.88 TP53
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.88 CYP21A2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.88 CYP21A2

MGI Mouse Phenotypes related to Leydig Cell Tumor:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 AFP CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1
2 nervous system MP:0003631 10.23 CALB2 CYP11A1 CYP19A1 ESR1 GNRH1 KIT
3 normal MP:0002873 10.22 CALB2 CYP11A1 CYP19A1 ESR1 GNRH1 INHA
4 growth/size/body region MP:0005378 10.18 CYP11A1 CYP17A1 CYP19A1 CYP21A2 ESR1 GNRH1
5 liver/biliary system MP:0005370 10.17 AFP CYP11A1 CYP19A1 ESR1 GNRH1 INHA
6 endocrine/exocrine gland MP:0005379 10.17 AFP CYP11A1 CYP19A1 ESR1 GNRH1 INHA
7 neoplasm MP:0002006 10.1 AFP ESR1 GNRH1 INHA KIT PRL
8 behavior/neurological MP:0005386 10.03 AFP CALB2 CYP11A1 CYP17A1 CYP19A1 CYP21A2
9 digestive/alimentary MP:0005381 9.86 CYP19A1 ESR1 GNRH1 INHA KIT LHCGR
10 reproductive system MP:0005389 9.83 AFP CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1
11 skeleton MP:0005390 9.32 CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1 INHA

Drugs & Therapeutics for Leydig Cell Tumor

Drugs for Leydig Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
2
Nivolumab Approved Phase 2 946414-94-4
3
Ipilimumab Approved Phase 2 477202-00-9
4
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
5
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
6
Bleomycin Approved, Investigational Phase 2 9041-93-4, 11056-06-7 5360373
7
Etoposide Approved Phase 2 33419-42-0 36462
8
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
9 Immunoglobulins, Intravenous Phase 2
10 Immunoglobulin G Phase 2
11 Angiogenesis Inhibitors Phase 2
12 Immunologic Factors Phase 2
13 Endothelial Growth Factors Phase 2
14 Mitogens Phase 2
15 Immunoglobulins Phase 2
16 Antibodies, Monoclonal Phase 2
17 Antibodies Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19 Immune Checkpoint Inhibitors Phase 2
20 Anti-Bacterial Agents Phase 2
21 Albumin-Bound Paclitaxel Phase 2
22
Etoposide phosphate Phase 2 16760419
23 Antimitotic Agents Phase 2
24 Tubulin Modulators Phase 2
25 Antibiotics, Antitubercular Phase 2
26
Gemcitabine Approved Phase 1 95058-81-4, 122111-03-9 60750
27 Antiviral Agents Phase 1
28 Anti-Infective Agents Phase 1
29 Antimetabolites Phase 1
30 Immunosuppressive Agents Phase 1
31
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
32
Vincristine Approved, Investigational 2068-78-2, 57-22-7 5978
33
Dactinomycin Approved, Investigational 50-76-0 2019 457193
34
Ifosfamide Approved 3778-73-2 3690
35
Doxorubicin Approved, Investigational 23214-92-8 31703
36
Palifosfamide Investigational 31645-39-3 100427
37 Liposomal doxorubicin

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
2 Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy Completed NCT00006227 Phase 2 Paclitaxel
3 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
4 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Active, not recruiting NCT01042522 Phase 2 Carboplatin;Cisplatin;Etoposide Phosphate;Paclitaxel
5 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
6 DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood Completed NCT01572467
7 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
8 International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions) Recruiting NCT03382158
9 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
10 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Leydig Cell Tumor

Cochrane evidence based reviews: leydig cell tumor

Genetic Tests for Leydig Cell Tumor

Anatomical Context for Leydig Cell Tumor

Organs/tissues related to Leydig Cell Tumor:

FMA: Ovary
MalaCards : Ovary, Testis, Breast, Endothelial, Testes, Cervix, Skeletal Muscle

Publications for Leydig Cell Tumor

Articles related to Leydig Cell Tumor:

(show top 50) (show all 1040)
# Title Authors PMID Year
1
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. 53 62
19679653 2009
2
Leydig cell tumor and malignant lymphoma in a patient with nonclassical 21-hydroxylase deficiency. 53 62
19367056 2009
3
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor. 53 62
17656605 2007
4
Possible mechanism for testicular focal necrosis induced by hCG in rats. 53 62
17077584 2006
5
Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. 53 62
15753388 2005
6
Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. 53 62
9253328 1997
7
Occurrence of FSH, inhibin and other hypothalamic-pituitary-intestinal hormones in normal fertility, subfertility, and tumors of human testes. 53 62
7749434 1995
8
Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. 53 62
8462465 1993
9
Extraadrenal expression of steroid 21-hydroxylase and 11 beta-hydroxylase by a benign testicular Leydig cell tumor. 53 62
1751389 1991
10
Leydig cell tumor estrogen secretion: suppression by a gonadotropin releasing hormone agonist. 53 62
1940064 1991
11
Measurement of circulating parathyroid hormone-related protein in rats with humoral hypercalcemia of malignancy using a two-site immunoradiometric assay. 53 62
2387260 1990
12
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line. 53 62
2340950 1990
13
Histidine decarboxylase inhibitors: a novel therapeutic option for the treatment of leydigioma. 62
36069766 2022
14
11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism. 62
36239921 2022
15
Embryonal Rhabdomyosarcoma of the Uterine Cervix: A Clinicopathologic Study of 94 Cases Emphasizing Issues in Differential Diagnosis Staging, and Prognostic Factors. 62
35941719 2022
16
DICER1 mutation in recurrent ovarian Sertoli-Leydig cell tumor: a case report. 62
36402443 2022
17
Pleuropulmonary blastoma (PPB) and other DICER1-associated high-grade malignancies are morphologically, genetically and epigenetically related - A comparative study of 4 PPBs and 6 sarcomas. 62
35779311 2022
18
Precocious Puberty in a Boy With Bilateral Leydig Cell Tumors due to a Somatic Gain-of-Function LHCGR Variant. 62
36111273 2022
19
Is testis sparing surgery safe in patients with incidental small testicular lesions referring to a fertility center? A retrospective analysis reporting factors correlated to malignancy and long-term oncological outcomes. 62
36075820 2022
20
Ovarian Sertoli-Leydig cell tumor: A case report. 62
36064481 2022
21
Exogenous cholesterol acquisition signaling in LH-responsive MA-10 Leydig cells and in adult mice. 62
35900012 2022
22
DICER1-associated Tumors in the Female Genital Tract: Molecular Basis, Clinicopathologic Features, and Differential Diagnosis. 62
35778792 2022
23
First Evidence of the Expression and Localization of Prothymosin α in Human Testis and Its Involvement in Testicular Cancers. 62
36139050 2022
24
DICER1-Altered Extraovarian Moderately Differentiated Sertoli-Leydig Cell Tumor: Report of a Rare Case. 62
36044308 2022
25
An Unusual Enteric Yolk Sac Tumor: First Report of an Ovarian Germ Cell Tumor Associated With a Germline Pathogenic Variant in DICER1. 62
34380971 2022
26
Testicular Lesions in Infertile Men. 62
34935941 2022
27
Collision Tumor of the Ovary Involving Sertoli-Leydig Cell Tumor and High-Grade Serous Carcinoma-Report of the First Case. 62
35838626 2022
28
Precocious puberty related to Leydig cell testicular tumor: the diagnostic imaging keys. 62
35550623 2022
29
Anastomosing Hemangioma of the Ovary With Leydig Cell Hyperplasia: A Clinicopathologic Study of 12 Cases. 62
35512214 2022
30
Bilateral congenital cryptorchidism and unilateral Leydig cell tumor in an adult presenting with gynecomastia and primary infertility: A case report. 62
35303605 2022
31
Yolk Sac Tumor of the Ovary: A Report of 150 Cases and Review of the Literature. 62
34469331 2022
32
Transcriptomic analysis of MA-10 tumor Leydig cells treated with adipose derived hormones adiponectin and resistin. 62
34929619 2022
33
Gonadal tumor risk in pediatric and adolescent phenotypic females with disorders of sex development and Y chromosomal constitution with different genetic etiologies. 62
35935368 2022
34
Complete androgen insensitivity syndrome - rare case of malignancy of dysgenetic gonads. 62
35896396 2022
35
A Matter of Time: Delayed Presentation and Rapid Progression from Gonadotropin-Independent to Gonadotropin-Dependent Precocious Puberty following Successful Treatment for a Leydig Cell Tumor. 62
35036017 2022
36
Bilateral testicular Leydig cell hyperplasia presented incidentally: A case report. 62
34968979 2022
37
15-Year-Old Patient with an Unusual Alpha-Fetoprotein-Producing Sertoli-Leydig Cell Tumor of Ovary. 62
35450124 2022
38
Testicular cancer among Saudi adults: Hands on a nationwide Cancer Registry over 10 years. 62
36353476 2022
39
DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. 62
34599283 2022
40
Leydig Cell Tumor-Induced Gonadotropin-Independent Precocious Puberty Progressing to Gonadotropin-Dependent Precocious Puberty Post Orchiectomy: Out of the Frying Pan Into the Fire. 62
35165615 2022
41
cAMP-specific phosphodiesterase 8A and 8B isoforms are differentially expressed in human testis and Leydig cell tumor. 62
36277728 2022
42
Testis-sparing surgery in children with testicular tumors: A systematic review and meta-analysis. 62
33893031 2021
43
Clinical heterogeneity and reduced penetrance in DICER1 syndrome: a report of three families. 62
34761719 2021
44
Effect of androgens on Sertoli cell maturation in human testis from birth to puberty. 62
34906089 2021
45
Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation. 62
34398502 2021
46
Krukenberg Tumor of Ovary During Pregnancy: Learning From A Mistake. 62
33252404 2021
47
A case of neoplastic synchronism in a dog. 62
34411998 2021
48
Postmenopausal women with hyperandrogenemia: Three case reports. 62
34754857 2021
49
Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. 62
34103665 2021
50
Primary Biphasic Hepatic Sarcoma in DICER1 Syndrome. 62
33872107 2021

Variations for Leydig Cell Tumor

Expression for Leydig Cell Tumor

Search GEO for disease gene expression data for Leydig Cell Tumor.

Pathways for Leydig Cell Tumor

Pathways related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 12.27 STAR CYP19A1 CYP17A1 CYP11A1
3 11.59 STAR CYP21A2 CYP11A1
4 11.47 TP53 PRL AFP
5 11.01 NR5A1 LHCGR INHA CYP19A1
6
Show member pathways
11.01 STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1
7 10.79 CYP21A2 CYP19A1 CYP17A1 CYP11A1
8 10.51 LHCGR GNRH1
9 10.47 STAR CYP17A1 CYP11A1
10 9.92 ESR1 CYP19A1

GO Terms for Leydig Cell Tumor

Biological processes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ovarian follicle development GO:0001541 9.93 LHCGR KIT INHA
2 sterol metabolic process GO:0016125 9.85 CYP21A2 CYP19A1 CYP11A1
3 female gonad development GO:0008585 9.8 NR5A1 LHCGR CYP19A1
4 uterus development GO:0060065 9.8 LHCGR ESR1 CYP19A1
5 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.73 TP53 ESR1
6 male gonad development GO:0008584 9.73 NR5A1 LHCGR KIT INSL3 INHA ESR1
7 negative regulation of miRNA maturation GO:1903799 9.65 TP53 ESR1
8 regulation of steroid biosynthetic process GO:0050810 9.65 LHCGR NR5A1 STAR
9 glucocorticoid biosynthetic process GO:0006704 9.63 CYP21A2 CYP17A1 CYP11A1
10 steroid biosynthetic process GO:0006694 9.28 STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1

Molecular functions related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.92 CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 iron ion binding GO:0005506 9.86 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 monooxygenase activity GO:0004497 9.46 CYP21A2 CYP19A1 CYP17A1 CYP11A1
4 hormone activity GO:0005179 9.32 PTHLH PRL INSL3 INHA GNRH1
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP21A2 CYP19A1 CYP17A1 CYP11A1

Sources for Leydig Cell Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....